AbbVie's Blood Cancer Combo Therapy Fails in Late-Stage Study

AbbVie has said a late-stage study of its experimental combination therapy failed to meaningfully increase the survival rate of patients without the disease worsening.
Reuters Health Information

source https://www.medscape.com/s/viewarticle/996945?src=rss

Comments

Popular posts from this blog

RA and RA-ILD Linked to Higher Lung Cancer Risk

DC’s Harllee Harper Is Using Public Health Tools to Prevent Gun Violence. Will It Work?